Each cycle is 14?days

Each cycle is 14?days. angiogenesis. VEGF-A inhibition with bevacizumab has shown to increase the immune cell infiltration, providing a solid rationale for combining VEGF targeted agents with immune checkpoint inhibitors. Based on these evidences, we explore the combination of triplet chemotherapy (FOLFOXIRI) with bevacizumab and nivolumab in pts. with mCRC mutant regardless of microsatellite status. Methods/design This is a prospective, open-label, multicentric phase II trial where pts. with mCRC mutated, in first line will receive nivolumab in combination with FOLFOXIRI/bevacizumab every 2?weeks for 8?cycles followed by maintenance with bevacizumab plus nivolumab every 2?weeks. Bevacizumab will be administered intravenously at dose of 5?mg/kg every 2?weeks and nivolumab intravenously as a flat dose of 240?mg every 2?weeks. The primary endpoint is the overall response rate (ORR). This study hypothesis is that the treatment is able to improve the ORR from Eprosartan mesylate 66 to 80%. Secondary endpoints include OS, safety, time to progression, duration of response. Collateral translational studies evaluate the i) tumor mutational burden, and ii) genetic alterations by circulating free DNA (cfDNA) obtained from plasma samples. The trial is open to enrollment, 9 of planned 70 pts. have been enrolled. Trial registration NIVACOR is registered at ClinicalTrials.gov: “type”:”clinical-trial”,”attrs”:”text”:”NCT04072198″,”term_id”:”NCT04072198″NCT04072198, August 28, 2019. gene (mutations is the only predictive marker of response to the anti-antibodies, cetuximab and panitumumab [4, 5]. The second potential biomarker in mCRC is mutated in 5C11% of cases [6]. The point mutation is the most common alteration and believed to be mutually exclusive with exon 2 mutations [7]. Accordingly, several clinical trials have highlighted the negative prognostic role of the mutation associated with high mortality [8]. In patients who harbor mutant tumors, the addition of anti-vascular growth factor (VEGF) antibody to cytotoxic drugs based on fluorouracil/levofolinate/irinotecan or oxaliplatin, has become Rabbit Polyclonal to OR13C4 one of the standard treatments in first-line of mCRC [9]. Several randomized studies, have Eprosartan mesylate proved that the triplet of chemotherapy with fluorouracil/levofolinate/irinotecan/oxaliplatin (FOLFOXIRI) combined to bevacizumab is more effective than doublet of chemotherapy plus bevacizumab, and this combination was well tolerated as first-line treatment in selected fit patients [10, 11]. In the TRIBE study [9], a phase III study, in first-line setting the treatment with FOLFOXIRI plus bevacizumab improved the primary endpoint, progression-free survival (PFS), compared with FOLFIRI (fluorouracil, leucovorin, and irinotecan) plus bevacizumab (HR 0.75; 95% CI 0.62C0.90; and wild-type subgroups compared to mutated and mutated subgroups (37.1?months vs. 25.6?months vs. 13.4?months), respectively [12]. In the VOLFI study [13], a phase II, patients affected by wild type mCRC treated in first line with modified-FOLFOXIRI (m-FOLFOXIRI) plus an anti-EGFR antibody, panitumumab, presented a significantly improved the ORR (87.3%) compared to control arm (60.6%) both investigator and centrally assessment (95% CI, 1.61C12.38; Overall response rate, Progression free survival, Overall survival, Not estimable, Not reached, Median Table 2 Clinical Trials ongoing in mCRC of immune-checkpoint inhibitors as single agents or in combination with chemotherapy mutated. Methods Protocol overview/study treatment This is a prospective, open-label, multicentric phase II trial in which pts. with or mutated will receive nivolumab in combination with FOLFOXIRI/bevacizumab as first line treatment. Study screening will take place within 28? days prior to initiation of study treatment. At screening, every patient must have local known status. A centralized review of status will be performed. Eligible pts. will be enrolled and begin treatment with FOLFOXIRI/bevacizumab plus Eprosartan mesylate nivolumab every 2?weeks for 8?cycles followed by maintenance with bevacizumab plus nivolumab every 2?weeks until disease progression, unacceptable toxicity or patient/physician decision. Bevacizumab will be administered intravenously at dose of 5?mg/kg every 2?weeks. Nivolumab will be administered intravenously at flat dose of 240?mg every 2?weeks. FOLFOXIRI will be administered as 165?mg/m2 intravenous infusion of irinotecan for 60?min, followed by an 85?mg/m2 intravenous infusion of oxaliplatin given concurrently with leucovorin at a dose of 200?mg/m2 for 120?min, followed by a 3200?mg/m2 continuous infusion of fluorouracil for 48?h (Fig.?1). Open in a separate window Fig. 1 Study Design. Primary Endpoint: Overall Response Rate (ORR) per investigator assessment (RECIST v1.1). *SD: stable disease, RP: partial response, RC: complete response During the protocols treatment, pts. will be followed for safety based on Adverse Event (AE) assessments including vital signs, physical findings and clinical laboratory test results. In order to guarantee the safety of pts., the enrolment will be stopped when the 10th patient will start treatment. An Independent Monitoring Committee will evaluate the safety data.